Care4AD + DiMe

For over a decade, we've been working to improve the lives of patients with Alzheimer's Disease and Related Dementias (ADRD). Today we're pleased to announce a new NIH grant award to develop an innovative care management platform for older adults including those with ADRD, and a partnership with the Digital Medicine Society (DiME) to develop digital health measures and biomarkers for ADRD. Details below!

ADRD Care Coordination and Management Platform 

We're excited to announce a ~$3M NIH grant to develop Nili, a care coordination and management platform designed to reduce caregiver burden while promoting healthier living for older adults including those with dementia.

Nili is undergoing clinical validation in a 6-month randomized controlled trial with 100 mild-to-moderately-severe-dementia participants. The clinical trial will examine changes in caregiver burden and stress when using Nili, as well as improvements in the health and safety of older adults with dementia.  

Nili was developed in collaboration with geriatric and dementia care experts at Baylor College of Medicine, with support from the National Institute on Aging, National Institutes of Health, grant #R44AG066360.

Partnership with the Digital Medicine Society (DiME)

We are excited to participate with the pre-competitive Digital Measures Development ADRD project which aims to expedite progress of ADRD research, treatment, and care. We are excited to leverage our industry knowledge and digital biomarker database to further facilitate the recognition and acceptance of digital biomarkers for clinical trials and research in dementia and ADRD. 

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that develops and provides end-to-end solutions and services for the collection of digital measures and biomarkers in clinical trials and research. All components of BioSensics solutions, including the wearable sensors, software, and algorithms are developed and validated by BioSensics. Our experienced research team provides comprehensive technical and scientific consulting, including study design and protocol development support, as well as statistical analysis. In addition, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

The U.S. National Institute of Health (NIH) has awarded BioSensics over $50M to support its research and development programs. In 2022, NIH selected BioSensics to develop remote measurement technologies for use in clinical trials in individuals with rare diseases.